Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1990 Jan;99(1):113–118. doi: 10.1111/j.1476-5381.1990.tb14663.x

2-substituted indazolinones: orally active and selective 5-lipoxygenase inhibitors with anti-inflammatory activity.

S J Foster 1, P Bruneau 1, E R Walker 1, R M McMillan 1
PMCID: PMC1917488  PMID: 2110012

Abstract

1. This paper describes the pharmacological profile of ICI207968, a novel, orally-active and selective inhibitor of 5-lipoxygenase. 2. Inhibition of leukotriene B4 (LTB4) synthesis by 2-substituted indazolinones was not directly related to redox potential but was critically dependent on the nature of the N2 substituent. 2-(3-Pyridylmethyl)-indazolinone (ICI207968) combined selectivity and oral potency. 3. In several in vitro systems ICI207968 exhibited similar lipoxygenase inhibitory potency (IC50 values from 1.5 microM to 6.0 microM) and was approximately 300 times less potent against cyclo-oxygenase, as measured by inhibition of prostaglandin E2 (PGE2) synthesis. 4. ICI207968 also produced selective lipoxygenase inhibition following oral administration in the rat. ED50 values of 2.5, 10 and 25 mg kg-1 p.o. for inhibition of LTB4 release from A23187-stimulated blood were obtained 1, 3 and 5 h after dosing. The compound did not inhibit PGE2 synthesis at oral doses up to 300 mg kg-1. 5. Co-administration of ICI207968 with arachidonic acid, into rabbit dermis, potently inhibited both plasma extravasation and polymorphonuclear leucocyte (PMNL) infiltration induced by this inflammatory fatty acid. The anti-inflammatory potency of a number of intradermally administered indazolinones, with similar redox potentials, was related to their inhibitory potency against leukotriene generation in blood. Oral administration of ICI207968 (100 mg kg-1) in the rabbit inhibited ex vivo leukotriene generation in blood and arachidonic acid-induced skin inflammation. 6. These data demonstrate that ICI207968 is an orally active and selective inhibitor of 5-lipoxygenase which has anti-inflammatory properties.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
113

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aharony D., Stein R. L. Kinetic mechanism of guinea pig neutrophil 5-lipoxygenase. J Biol Chem. 1986 Sep 5;261(25):11512–11519. [PubMed] [Google Scholar]
  2. Aked D. M., Foster S. J. Leukotriene B4 and prostaglandin E2 mediate the inflammatory response of rabbit skin to intradermal arachidonic acid. Br J Pharmacol. 1987 Nov;92(3):545–552. doi: 10.1111/j.1476-5381.1987.tb11355.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Aked D., Foster S. J., Howarth A., McCormick M. E., Potts H. C. The inflammatory response of rabbit skin to topical arachidonic acid and its pharmacological modulation. Br J Pharmacol. 1986 Oct;89(2):431–438. doi: 10.1111/j.1476-5381.1986.tb10277.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bach M. K. Prospects for the inhibition of leukotriene synthesis. Biochem Pharmacol. 1984 Feb 15;33(4):515–521. doi: 10.1016/0006-2952(84)90300-9. [DOI] [PubMed] [Google Scholar]
  5. Borgeat P., Samuelsson B. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes. Formation of a novel dihydroxyeicosatetraenoic acid. J Biol Chem. 1979 Apr 25;254(8):2643–2646. [PubMed] [Google Scholar]
  6. Bray M. A., Ford-Hutchinson A. W., Smith M. J. Leukotriene B4: an inflammatory mediator in vivo. Prostaglandins. 1981 Aug;22(2):213–222. doi: 10.1016/0090-6980(81)90036-8. [DOI] [PubMed] [Google Scholar]
  7. Bray M. A. Leukotrienes in inflammation. Agents Actions. 1986 Oct;19(1-2):87–99. doi: 10.1007/BF01977263. [DOI] [PubMed] [Google Scholar]
  8. Camp R. D., Coutts A. A., Greaves M. W., Kay A. B., Walport M. J. Responses of human skin to intradermal injection of leukotrienes C4, D4 and B4. Br J Pharmacol. 1983 Nov;80(3):497–502. doi: 10.1111/j.1476-5381.1983.tb10721.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Carey F., Forder R. A. Radioimmunoassay of LTB4 and 6-trans LTB4: analytical and pharmacological characterisation of immunoreactive LTB4 in ionophore stimulated human blood. Prostaglandins Leukot Med. 1986 Apr;22(1):57–70. doi: 10.1016/0262-1746(86)90022-3. [DOI] [PubMed] [Google Scholar]
  10. DiMartino M. J., Griswold D. E., Berkowitz B. A., Poste G., Hanna N. Pharmacologic characterization of the antiinflammatory properties of a new dual inhibitor of lipoxygenase and cyclooxygenase. Agents Actions. 1987 Feb;20(1-2):113–123. doi: 10.1007/BF01965633. [DOI] [PubMed] [Google Scholar]
  11. Foster S. J., McCormick M. E., Howarth A., Aked D. Leukocyte recruitment in the subcutaneous sponge implant model of acute inflammation in the rat is not mediated by leukotriene B1. Biochem Pharmacol. 1986 May 15;35(10):1709–1717. doi: 10.1016/0006-2952(86)90328-x. [DOI] [PubMed] [Google Scholar]
  12. Griswold D. E., Marshall P. J., Webb E. F., Godfrey R., Newton J., Jr, DiMartino M. J., Sarau H. M., Gleason J. G., Poste G., Hanna N. SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. Biochem Pharmacol. 1987 Oct 15;36(20):3463–3470. doi: 10.1016/0006-2952(87)90327-3. [DOI] [PubMed] [Google Scholar]
  13. Higgs G. A., Flower R. J., Vane J. R. A new approach to anti-inflammatory drugs. Biochem Pharmacol. 1979 Jun 15;28(12):1959–1961. doi: 10.1016/0006-2952(79)90651-8. [DOI] [PubMed] [Google Scholar]
  14. McMillan R. M., Foster S. J. Leukotriene B4 and inflammatory disease. Agents Actions. 1988 Jun;24(1-2):114–119. doi: 10.1007/BF01968088. [DOI] [PubMed] [Google Scholar]
  15. McMillan R. M., Masters D. J., Vickers V. C., Dicken M. P., Jacobs V. N. Metabolism of unsaturated fatty acids by RBL-1 5-lipoxygenase: influence of substrate solubility and product inactivation. Biochim Biophys Acta. 1989 Sep 25;1005(2):170–176. doi: 10.1016/0005-2760(89)90183-5. [DOI] [PubMed] [Google Scholar]
  16. Rampart M., Williams T. J. Evidence that neutrophil accumulation induced by interleukin-1 requires both local protein biosynthesis and neutrophil CD18 antigen expression in vivo. Br J Pharmacol. 1988 Aug;94(4):1143–1148. doi: 10.1111/j.1476-5381.1988.tb11632.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rollins T. E., Zanolari B., Springer M. S., Guindon Y., Zamboni R., Lau C. K., Rokach J. Synthetic leukotriene B4 is a potent chemotaxin but a weak secretagogue for human PMN. Prostaglandins. 1983 Feb;25(2):281–289. doi: 10.1016/0090-6980(83)90110-7. [DOI] [PubMed] [Google Scholar]
  18. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983 May 6;220(4597):568–575. doi: 10.1126/science.6301011. [DOI] [PubMed] [Google Scholar]
  19. Soter N. A., Lewis R. A., Corey E. J., Austen K. F. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol. 1983 Feb;80(2):115–119. doi: 10.1111/1523-1747.ep12531738. [DOI] [PubMed] [Google Scholar]
  20. Tai H. H., Tai C. L., Lee N. Selective inhibition of thromboxane synthetase by pyridine and its derivatives. Arch Biochem Biophys. 1980 Sep;203(2):758–763. doi: 10.1016/0003-9861(80)90236-2. [DOI] [PubMed] [Google Scholar]
  21. Tateson J. E., Randall R. W., Reynolds C. H., Jackson W. P., Bhattacherjee P., Salmon J. A., Garland L. G. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br J Pharmacol. 1988 Jun;94(2):528–539. doi: 10.1111/j.1476-5381.1988.tb11557.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ueno A., Tanaka K., Katori M., Hayashi M., Arai Y. Species difference in increased vascular permeability by synthetic leukotriene C4 and D4. Prostaglandins. 1981 Apr;21(4):637–648. doi: 10.1016/0090-6980(81)90012-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES